LeMaitre Vascular (NASDAQ:LMAT) Upgraded at First Analysis

First Analysis upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from an outperform rating to a strong-buy rating in a research note issued to investors on Monday, BenzingaRatingsTable reports. They currently have $37.00 price objective on the medical instruments supplier’s stock.

LMAT has been the topic of a number of other research reports. BidaskClub raised LeMaitre Vascular from a buy rating to a strong-buy rating in a research report on Friday, September 13th. ValuEngine downgraded LeMaitre Vascular from a buy rating to a hold rating in a research report on Monday, October 7th. Barrington Research reissued an outperform rating and set a $37.00 price target (up previously from $32.00) on shares of LeMaitre Vascular in a research report on Thursday, July 25th. Zacks Investment Research downgraded LeMaitre Vascular from a strong-buy rating to a hold rating in a research report on Wednesday, September 25th. Finally, Lake Street Capital boosted their price target on LeMaitre Vascular from $27.00 to $34.00 and gave the stock a hold rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $36.50.

NASDAQ:LMAT opened at $32.54 on Monday. The stock’s 50-day simple moving average is $32.94 and its 200 day simple moving average is $29.95. The company has a market cap of $621.80 million, a P/E ratio of 38.74, a P/E/G ratio of 3.64 and a beta of 1.22. LeMaitre Vascular has a 52-week low of $21.79 and a 52-week high of $36.06.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. The business had revenue of $29.48 million for the quarter, compared to the consensus estimate of $28.90 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 16.72%. LeMaitre Vascular’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. Research analysts anticipate that LeMaitre Vascular will post 0.86 EPS for the current year.

In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 66,037 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $34.45, for a total transaction of $2,274,974.65. Following the transaction, the chairman now owns 3,171,124 shares of the company’s stock, valued at $109,245,221.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence J. Jasinski sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $32.00, for a total value of $160,000.00. Following the transaction, the director now directly owns 10,833 shares in the company, valued at approximately $346,656. The disclosure for this sale can be found here. In the last three months, insiders have sold 129,654 shares of company stock worth $4,423,865. Company insiders own 19.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP grew its position in shares of LeMaitre Vascular by 36.0% in the first quarter. Marshall Wace LLP now owns 160,775 shares of the medical instruments supplier’s stock valued at $4,984,000 after purchasing an additional 42,560 shares during the last quarter. Marshall Wace North America L.P. bought a new stake in shares of LeMaitre Vascular in the first quarter valued at approximately $1,283,000. WINTON GROUP Ltd boosted its stake in shares of LeMaitre Vascular by 116.0% in the second quarter. WINTON GROUP Ltd now owns 23,514 shares of the medical instruments supplier’s stock valued at $658,000 after buying an additional 12,627 shares during the period. Capital Impact Advisors LLC boosted its stake in shares of LeMaitre Vascular by 9.3% in the second quarter. Capital Impact Advisors LLC now owns 67,985 shares of the medical instruments supplier’s stock valued at $1,893,000 after buying an additional 5,780 shares during the period. Finally, Summit Creek Advisors LLC boosted its stake in shares of LeMaitre Vascular by 0.3% in the second quarter. Summit Creek Advisors LLC now owns 230,539 shares of the medical instruments supplier’s stock valued at $6,450,000 after buying an additional 630 shares during the period. 78.60% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: What is the Current Ratio?

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.